In light of the potential immune-boosting capability of MWA and the hypofunction of CAR T cells in solid tumours, the combination of MWA and AXL-CAR T cells may be an attractive approach to treat NSCLC. This evidence concerns the gene AXL and non-small cell lung carcinoma.